TickerFactsScreenerDevelopers

SELLAS Life Sciences Group, Inc. (SLS) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2009: $5.68M2010: $6.89M2011: $47.79M2012: $32.81M2013: $47.79M2014: $23.65M2015: $1.40M2016: $5.96M2017: $2.32M2018: $5.34M2019: $7.28M2020: $35.30M2021: $21.36M2022: $17.12M2023: $2.53M2024: $13.89M2025: $71.79M$71.79M
2009Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$71.79M+417.0%
2024$13.89M+448.9%
2023$2.53M-85.2%
2022$17.12M-19.8%
2021$21.36M-39.5%
2020$35.30M+385.1%
2019$7.28M+36.4%
2018$5.34M+130.1%
2017$2.32M-61.1%
2016$5.96M+326.8%
2015$1.40M-94.1%
2014$23.65M-50.5%
2013$47.79M+45.7%
2012$32.81M-31.3%
2011$47.79M+593.5%
2010$6.89M+21.2%
2009$5.68M—